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Abstract 
 
Bisnaphthalimidopropyl diaminodicyclohexylmethane (BNIPDaCHM) 
bisintercalates to DNA and is a potential anti-cancer therapeutic. In an attempt to 
elucidate the mechanism(s) underlying the potential of BNIPDaCHM; earlier work 
was extended to investigate its effect on DNA damage and repair as well as cell cycle 
modulation, in a triple negative breast cancer (TNBC) cell line in vitro. 
BNIPDaCHM significantly decreased cell viability in a concentration (≥ 5 
µM) and time (≥ 24 hours) dependent manner. The mechanism of this growth 
inhibition involved alterations to cell cycle progression, an increase in the sub-G1 
population and changes to plasma membrane integrity/permeability observed by flow 
cytometry and fluorescence microscopy with acridine orange/ethidium bromide 
staining. Using single cell gel electrophoresis (Comet assay) and fluorescence 
microscopy to detect γ-H2AX-foci expression; it was found that after 4 hours, ≥ 0.1 
µM BNIPDaCHM treatment-induced significant DNA double strand breaks (DSBs). 
Moreover, exposure to a non-genotoxic concentration of BNIPDaCHM induced a 
significant decrease in the repair of oxidative DNA strand breaks induced by 
hydrogen peroxide. Also, BNIPDaCHM-treatment induced a significant time 
dependent increase in p21Waf/Cip1 mRNA expression but, did not alter p53 mRNA 
expression. 
In conclusion, BNIPDaCHM treatment in MDA-MB-231 cells was associated 
with a significant induction of DNA DSBs and inhibition of DNA repair at non-
genotoxic concentrations via p53-independent expression of p21Waf1/Cip1. The latter 
may be a consequence of novel interactions between BNIPDaCHM and MDA-MB-
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231 cells which adds to the spectrum of therapeutically relevant activities that may be 
exploited in the future design and development of naphthalimide-based therapeutics.  
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1. Introduction 
 
Breast cancer (BC) is the most frequently diagnosed cancer, as well as, the 
leading cause of death in the female population [1]. Triple negative breast cancer 
(TNBC) accounts for 12-20% of all BCs and, in this phenotype of BC, cells lack the 
expression of estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2/neu) [2, 3]. Drug-resistant TNBCs 
metastasise rapidly, have poor prognosis which renders them extremely difficult to 
treat and, they also appear to be occurring more frequently in younger women [3, 4]. 
Therefore, it is crucial to develop and test new, selective and efficient anti-cancer 
drugs that counteract TNBC cell growth, but also limit side effects which are often 
unmanageable for patients. 
 Chemotherapy, using a broad spectrum of cytotoxic drugs, such as, 
doxorubicin, daunorubicin, or epirubicin, is the primary treatment offered to TNBC 
patients. The therapeutic use of these drugs relies on their ability to interact and target 
DNA by intercalation [5] thus, interfering with transcription and/or replication. 
Notably, this mode of action remains the most effective treatment for, not only breast 
cancer, but also acute leukaemia, ovarian and bladder cancers [6].  
Bisnaphthalimides constitute a promising group of anti-cancer compounds 
which target DNA by intercalation and have strong cytotoxic properties observed in 
vitro [7, 8, 9]. Typically, these compounds consist of two naphthalamido-
chromophore units linked by alkyl chains containing at least one amino group [10]. 
Noteworthy examples are Elinafide (LU79553) [11, 12] and Bisnafide (DMP-840) 
[13] which progressed to Phase I and II clinical trials for advanced solid cancers. 
Despite encouraging preliminary anti-tumour activities, problems with efficacy and 
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adverse dose-limiting toxicities, for example, myelosuppression [11, 13] and neuro-
muscular toxicity [12] of a cumulative nature were observed. To address such issues, 
more research is required in order to improve where these former bisnaphthalimide 
derivatives have clinically failed.  
For a number of years, our research group have been designing and 
synthesising bisnaphthalimidopropyl (BNIP) derivatives linked to natural polyamines 
[14, 15, 16], and to a selection of diamino and triamino alkyl chains [17, 18, 19, 20] 
which have enhanced aqueous solubility and strong DNA-binding affinities. BNIP 
derivatives were found to be more cytotoxic (IC50 values in the range of 4.9-12.7 µM) 
than the chemotherapy drug doxorubicin (IC50 value 14.4 µM) in breast cancer MDA-
MB-231 cells, after 24 hours [20]. Moreover, BNIP derivatives were less cytotoxic in 
non-tumourigenic breast epithelial MCF-10A cells than doxorubicin; which gave an 
indication of the selectivity of BNIP derivatives in both cancerous and surrounding 
healthy tissues [20]. 
DNA was suggested to be a potential target for BNIP derivatives by Barron et 
al. [20]; however, the specific mechanism by which DNA damage is induced has not 
been widely investigated. Recent alterations to the linker chain confirmed BNIP 
moiety is crucial for activity [20, 21]. Novel modifications to the linker chain, such as, 
introduction of a bicyclohexylmethane group (bisnaphthalimidopropyl 
diaminocyclohexylmethane; BNIPDaCHM) (Fig. 1.) - reduced the flexibility of the 
linker - but enhanced cellular uptake and biological activity in vitro against MDA-
MB-231 cells [20]. Even though DNA is considered to be intrinsic to 
bisnaphthalimide derivative efficacy as observed in colon cancer cells [8, 22, 23, 24]; 
the relationship between bisnaphthalimide exposure and DNA stability in BC cells, 
particularly TNBC cells, has not been widely investigated. 
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This study aims to investigate, for the first time, the effect of BNIPDaCHM on 
DNA stability and repair, as well as, cell cycle modulation in one of the most 
commonly studied TNBC cell line (i.e., MDA-MB-231 cells) in vitro. These cells 
were selected to extend our previous work [20] and, also because the treatment of 
TNBC is associated with poor outcome and still lacks the benefit of targeted therapy. 
Therefore, treatment of TNBC is a significant clinical problem for which there is 
currently not an effective treatment option and so, investigating the effect of a 
potentially promising anti-cancer derivative in a TNBC cell line may address an 
important area of cancer research.   
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2. Materials and Methods 
 
2.1. Materials 
All chemicals and cell culture reagents were purchased from Sigma-Aldrich 
Ltd (Poole, UK) unless otherwise stated. Sterile, disposable cell culture plastics were 
obtained from Nunc (Fisher ThermoScientific, Loughborough, UK). BNIPDaCHM 
was synthesised and characterised as reported in Barron et al. [20]. Stock 
BNIPDaCHM (10 mM) was prepared in 50% (v/v) dimethyl sulfoxide (DMSO), 
stored at 4°C and diluted to the desired final concentrations in growth media 
containing serum.  
 
2.2. Cell culture 
Human breast epithelial MDA-MB-231 cancer cells were purchased from the 
European Collection of Cell Cultures (ECACC Catalogue No.: 92020424, Lot. No. 
05K032) (Public Health England, UK). MDA-MB-231 cells were maintained in 
RPMI-1640 medium (containing GlutaMAX™-1 with 25 mM HEPES) supplemented 
with 10% (v/v) foetal calf serum (FCS) and 1% (v/v) penicillin (100 
U/mL)/streptomycin (100 µg/mL).  
MDA-MB-231 cells were incubated at 37°C in a 5% CO2 air humidified 
atmosphere. Cells were media-changed and sub-cultured appropriately and all washes 
were performed with phosphate buffered saline (PBS). 
MDA-MB-231 cells were seeded in 96 well plates (8 x 103 cells/well) for 
cytotoxic studies; 24 well plates (8 x 104 cells/well) for  DNA damage (strand 
breakage), DNA repair and acridine orange/ethidium bromide staining; 6 well plates 
(4 x 105 cells/well) for annexin V conjugate labelled with fluorescein isothiocyanate 
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(Annexin V-FITC) flow cytometry experiments and 25 cm2 flasks (3.6 x 104 
cells/cm2) for cell cycle analysis and RNA expression.  Cells were allowed to adhere 
overnight. For the -H2AX-foci detection by fluorescent microscopy, MDA-MB-231 
cells were cultured overnight in 12-well plates to 70-80% confluency prior to 
treatment. 
DMSO, with or without BNIPDaCHM, was added to the monolayers at a 
volume not exceeding 0.5% (v/v) solvent, so that the final concentration of 
BNIPDaCHM was ≤ 5 µM when used in the DNA strand breakage, DNA repair, 
fluorescence microscopy, flow cytometry and RT-PCR experiments as detailed 
below. DMSO-treated cells were denoted as the control in all experiments. 
 
2.3. Cytotoxicity – MTT assay 
BNIPDaCHM cytotoxicity was quantified using the standard colourimetric 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [25]. MDA-
MB-231 cells were incubated with BNIPDaCHM (0-40 µM; for 4-72 hours) in 96 
well plates. After the desired incubation time, culture medium was removed, 100 µL 
MTT (1 mg/mL) solution added and incubated at 37 °C for 4 hours. The metabolised 
MTT product was dissolved in DMSO (100%, 200 µL) and quantified by measuring 
the absorbance at 560 nm in a plate reader (Bio-Tek, UK). The mean absorbance 
values for the negative control (DMSO-treated cells) were standardised as 100% (i.e., 
no growth inhibition) and the results for BNIPDaCHM expressed as % absorbance of 
DMSO-treated cells. The IC50 is the concentration of BNIPDaCHM required to inhibit 
cell growth by 50% of DMSO-treated cells.  
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2.4. Cell cycle analysis – Flow cytometry 
 Cell cycle progression was determined in MDA-MB-231 cells incubated with 
BNIPDaCHM (5 µM) or etoposide (10 µM; positive control) for 24 hours, at 37 °C. 
Medium was removed and collected and, cells washed twice with PBS. Both washes 
were collected and the cells detached using trypsin. The equivalent cells and washes 
were centrifuged at 2,500 rpm for 5 minutes, at 4 °C. Cell pellets were washed in PBS 
(1 mL) and centrifuged as before. The resultant cell pellets were resuspended in 100 
µL PBS and fixed with 70% (v/v) ice-cold ethanol (900 µL) at -20 °C for 2 hours. The 
cell pellets were centrifuged at 5,000 rpm for 5 minutes, at 4 °C. As before, cell 
pellets were washed in PBS (1 mL) and re-centrifuged at 5,000 rpm for 5 minutes, at 
4 °C. The cell pellet was resuspended in 500 µL PBS/DNA (1:1) extraction buffer 
(0.2 M Na2PO4, 4 mM citric acid, pH 7.8) and incubated for 5 minutes, at room 
temperature (RT). The extract was centrifuged at 5,000 rpm for 5 minutes, at 4 °C; the 
supernatant removed and the cell pellet resuspended in 500 µL DNA staining solution 
(0.2 mg/mL ribonuclease A (DNAse-free) and 20 µg/mL propidium iodide (PI)) and 
incubated for 30 minutes, at 4 °C, in the dark. PI stained nuclei were analysed by the 
Epics XL-MCL flow cytometer (Beckman-Coulter, UK). A total of 10,000 events 
were acquired with EXPO32 ADC XL 4 color and EXPO32 ADC analysis software 
(Beckman Coulter, UK). The percentage of cells with DNA content in sub-G1, G1, S 
and G2/M were calculated from histograms of linear FL-2 plots (575 nm) in the gated 
region.    
 
2.5. Acridine orange/ethidium bromide staining – Fluorescence microscopy  
MDA-MB-231 cells were incubated with BNIPDaCHM (0-5 µM; for 0.5, 6 
and 24 hours, at 37 °C) or etoposide (10 µM; for 24 hours, at 37 °C; positive control). 
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Medium was removed and cells washed twice with PBS. Changes to cell morphology, 
plasma membrane integrity and nuclear structure were assessed by acridine 
orange/ethidium bromide (AO/EtBr) staining (40 µL of 100 µg/mL solution to 1 mL 
PBS) using fluorescence microscopy (Leica DMIL fluorescence microscope (Leica 
Microsystems, Milton Keynes, UK) with a UV filter (excitation bandpass 450-490 nm 
and emission longpass 515 nm) and Leica DC 200 camera (Leica Microsystems, 
Milton Keynes, UK). 
 
2.6. Detection of apoptosis - Flow cytometry 
Detection of apoptotic cells, phosphatidylserine (PS) exposure and cell 
membrane integrity/permeability of BNIPDaCHM-treated MDA-MB-231 cells (0-5 
µM; for 0.5 hours, at 37 °C) were determined via Annexin V-FITC in conjunction 
with 7-amino actinomycin D (7-AAD) staining kit according to manufacturers 
instructions (Beckman Coulter, High Wycombe, UK). Briefly, cell pellets were 
resuspended in 100 µL ice-cold Binding Buffer (1x) with 10 µL Annexin V/FITC 
solution and 20 µL 7-AAD viability dye subsequently added. Pellets were mixed 
gently and incubated on ice for 15 minutes in the dark. Ice-cold binding buffer (1x; 
400 µL) was added, mixed gently and analysed using Epics XL-MCL flow cytometer 
(Beckman-Coulter, UK); with a total of 10,000 events acquired. Formaldehyde (3% 
v/v) was used as an experimental control to configure the gate settings due to its 
ability to induce maximal apoptotic cell death after 30 minutes. The FL-1 (525 nm) 
channel was gated for annexin V-FITC and FL-4 (675 nm) channel gated for 
detection of 7-AAD. The percentage of apoptotic and necrotic cells were analysed 
from histogram plots of LOG FL-1 (525 nm) and LOG FL-4 (675 nm), respectively. 
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2.7. DNA damage (strand breakage) – Comet assay 
MDA-MB-231 cells were incubated with BNIPDaCHM (0-10 µM; for up to 
24 hours, at 37 °C) or positive controls, camptothecin (10 µM for 2 hours, at 37 °C) or 
hydrogen peroxide (H2O2; 200 µM for 5 minutes, on ice). Human breast epithelial 
MCF-10A cells (purchased from the American Tissue Culture Collection (ATCC 
Catalogue No.: CRL-10317, Lot. No.: 3982356) are non-tumourigenic and were used 
as a normal breast cell line control. Cells were collected using trypsin and DNA 
damage assessed using single-cell gel electrophoresis (SCGE; Comet assay) under 
alkaline conditions as previously described by Singh et al. [26] and further adapted in 
Dance et al. [16] and Ralton et al. [19]. Quantification of DNA strand breaks was 
determined visually by fluorescence microscopy (Leica DMRB fluorescence 
microscope (Leica Microsystems, Milton Keynes, UK)) with D filter (excitation 
bandpass 355-425 nm and emission longpass 470 nm) and classified in order of the 
degree of DNA strand breaks, assessed by the relative intensity of fluorescence in the 
comet head and the length of the comet tail, and given a score of 0, 1, 2, 3 or 4 (from 
undamaged, 0, to maximally damaged, 4) [19]. One hundred comets were scored 
blind per sample, and hence, the total score of each sample can range from 0 (all 
undamaged) to 400 (all maximally damaged) [27].   
 
2.8. γ-H2AX-foci expression – Fluorescence microscopy 
MDA-MB-231 cells were incubated with BNIPDaCHM (0-5 µM; for up to 24 
hours, at 37 °C) or camptothecin (10 µM for 2 hours, at 37 °C; positive control). The 
medium was replaced and the cells left to recover for 2 hours. The medium was then 
removed and the cells washed 3 times with PBS. The cells were subsequently fixed 
with 4% (w/v) paraformaldehyde (Wako Pure Chemical Ind., Ltd, Osaka, Japan) for 
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30 minutes at RT. The cells were washed as before and permeabilised for 30 minutes 
with 0.1% (w/v) Triton-X in PBS (PBST) at RT. The cells were blocked with 5% 
blocking one buffer (BOB; Nacalai, Kyoto, Japan) in PBST for 30 minutes at RT. -
H2AX monoclonal antibody (clone JBW301; Millipore, Temecula, USA) was added 
at 1:200 in 5% BOB-PBST for 1 hour at RT. The cells were washed as previously 
described and the Alexa Fluor 488 goat anti-mouse IgG antibody (Invitrogen, 
Carlsbad, CA, USA) added at 1:200 for 1 hour at RT. The cells were washed as 
before and the samples mounted with 4’, 6-diamidino-2-phenylindole dihydrochloride 
(DAPI) Fluoromount-G (Southern-Biotech, Birmingham, AL, USA) and a glass 
slide placed over each sample. The cells were viewed using an Olympus IX71 
microscope: DAPI (excitation 330-385 nm and emission 420 nm) and for γ-H2AX-
foci (excitiation 470-495 nm and emission 510-550 nm). Images from one microscope 
field of view per sample were taken and analysed using QCapture Pro 6.0 (QImaging, 
BC, Canada). γ-H2AX stained nuclei and DAPI stained nuclei (i.e., total number of 
cells) were counted. The γ-H2AX stained nuclei/DAPI stained nuclei ratio was 
calculated and expressed as a percentage [28].  
 
2.9. DNA repair of hydrogen peroxide-induced DNA strand breakage – 
Comet assay  
MDA-MB-231 cells were incubated with BNIPDaCHM (nontoxic 
concentrations of 0.1 or 1 µM for 4 and 24 hours, respectively). Cells were washed 
twice with PBS before incubation with H2O2 (200 µM for 5 minutes on ice) to induce 
oxidative DNA damage. After 5 minutes, the medium and H2O2 were removed, cells 
washed twice with PBS and fresh RPMI medium added. Cells were incubated for up 
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to 24 hours, at 37 °C after which cells were collected (i.e., 0, 2, 4, 8 and 24 hours after 
addition of RPMI medium) and processed for SCGE as previously detailed.     
 
2.10. p53 and p21 gene expression – RT-PCR 
 Total RNA was extracted from BNIPDaCHM (5 µM) treated MDA-MB-231 
cells, after 1 or 4 hours, using TRIzol (Invitrogen, Paisley, UK) according to 
manufacturer’s instructions. Total RNA concentrations were quantified using a 
Heλios γ UV/Visible spectrophotometer (Thermo Electron Corporation, Madison, 
USA). Equal amounts of RNA (100 ng) were reverse-transcribed using 5x first strand 
buffer, dithiothreitol (DTT), deoxynucleotide triphosphate (dNTP’s) (Promega, 
Madison, USA), recombinant ribonuclease inhibitor RNaseOUT™ (Invitrogen, 
Paisley, UK), bovine serum albumin (BSA) (New England Biolabs Inc, Hitchin, UK), 
random hexadeoxynucleotides (Promega, Madison, USA) and Superscript™ III 
reverse transcription (RT) (Invitrogen, Paisley, UK) using an iCycler Thermal Cycler 
(Bio-Rad Laboratories, USA).   
 Expression of human p53, human p21Waf1/Cip1 and β-actin (Table 1) were 
studied by semi-quantitative PCR using an iCycler Thermal Cycler (Bio-Rad 
Laboratories, USA). The amplification conditions used were as follows: initial 
denaturation (4 minutes at 94 °C); followed by 25 cycles comprising of 1 minute at 94 
°C, 2 minutes at 59 °C and 2 minutes at 72 °C for p53 and p21Waf1/Cip1 or 25 cycles 
comprising 1 minute at 94 °C, 2 minutes at 68 °C and 2 minutes at 72 °C for β-actin; 
and 1 cycle of final extension (8 minutes at 72 °C). Amplification products were 
electrophoresed in 1.5% (w/v) agarose gels and visualised with ethidium bromide 
using a ChemiDoc EQ system (Bio-Rad Laboratories, Hemel Hempstead, UK) and 
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quantified using Quantity One (Version 4.5.0) software (Bio-Rad Laboratories, Hemel 
Hempstead, UK). 
 
2.11. Statistics 
Unless otherwise stated, each data set contained a minimum of two 
independent experiments, in which each experiment was comprised of at least 3 
internal replicates. Data are presented as mean ± SEM and, where appropriate, data 
was compared by Student t-test (Graphpad Prism) or by one-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparison post t-test (Graphpad Prism). P<0.05 
was considered to be statistically significant. 
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3. Results  
 
3.1. BNIPDaCHM treatment reduced cell viability 
The cytotoxicity of BNIPDaCHM (0.01-40 µM) was investigated in MDA-
MB-231 cells over 72 hours and quantified using the MTT assay (Fig. 2), where 
mitochondrial activity is assumed to reflect the rate of cell metabolism and, thus, the 
rate of enzymatic conversion is directly representative of cell viability. The 
percentage cell viability was normalised to DMSO-treated cells (i.e., control (0.2% 
(v/v) DMSO)).  
BNIPDaCHM significantly decreased cell viability in a concentration (≥ 5 
µM) and time (≥ 24 hours) dependent manner, compared to control cells. Cell 
viability was significantly decreased with 5 µM BNIPDaCHM; with a decrease of 21, 
46 and 60% after 24, 48 and 72 hours, respectively (Fig. 2). The IC50 values were 6.8, 
5.2 and 4.6 µM after 24, 48 and 72 hours, respectively (Table 2). 
From these results, ≤ 5 µM BNIPDaCHM concentrations were used in all 
subsequent experiments in this study. 
 
3.2. BNIPDaCHM treatment induces cell cycle instability and a loss of plasma 
membrane integrity 
 As increased proliferation is a characteristic common to tumour cells, which 
are more susceptible to cell cycle modulation, the effects of BNIPDaCHM treatment 
on the cell cycle of MDA-MB-231 cells was investigated using flow cytometry and PI 
staining (Figs. 3 and 4). PI is a DNA intercalator that can bind to DNA specifically 
following the loss of plasma membrane integrity; with the amount of PI proportional 
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to DNA content, which indicates the distribution of cells within the different cell 
cycle phases (Fig. 3A).  
BNIPDaCHM (5 µM) treatment significantly increased (31%) the sub-G1 
population (i.e., cells with low DNA content) and induced a significant decrease (22% 
and 8%) in the proportion of MDA-MB-231 cells in G1 and G2/M, respectively, 
compared to the control (DMSO-treated cells) (Fig. 3B). Cells in S phase were 
decreased, but not significantly, when compared to control cells (Fig. 3B). Treatment 
with etoposide (10 µM; positive control) increased (17%), the sub-G1 population but, 
not to the same extent as BNIPDaCHM. Also, cell arrest in S phase (8% increase) was 
observed. Thus, BNIPDaCHM and etoposide use differential mechanisms of action 
(Fig. 3B).  
Cell cycle checkpoints represent an intersection of cell survival and death 
where conditions for successful interphase and mitosis have to be favourable for 
complete cell division or cell death is triggered. In accordance with this and the 
finding that BNIPDaCHM increased the cell population in sub-G1; apoptosis was 
examined by fluorescence microscopy and flow cytometry to further determine the 
effects of BNIPDaCHM on early cell death in MDA-MB-231 cells (Fig. 4).  
The effect of BNIPDaCHM (1 or 5 µM; 0.5-24 hours) on chromatin changes 
in MDA-MB-231 cells relative to membrane integrity was demonstrated by 
fluorescence microscopy following AO/EtBr staining (Fig. 4A). Both AO and EtBr 
intercalate with DNA; AO fluoresces green in viable cells with intact membranes (i.e., 
viable and early apoptotic cells), whilst EtBr fluoresces orange in non-viable cells 
(i.e., late apoptosis and necrosis). EtBr can only be taken up in cells when plasma 
membrane integrity has been compromised. Membrane integrity was compromised 
with ≥ 1 µM BNIPDaCHM (Fig. 4A). After 0.5 hours, early apoptotic cells were 
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evident in a dose dependent manner in BNIPDaCHM-treated MDA-MB-231 cells, 
compared to control cells. After 6 hours, late apoptotic cells were evident; however, 
viable and early apoptotic cells were also present, in both control and BNIPDaCHM-
treated MDA-MB-231 cells. After 24 hours, viable, early apoptotic and late apoptotic 
cells were evident in control and BNIPDaCHM-treated MDA-MB-231 cells. A visible 
loss of cell number and cell shrinkage was observed with 5 µM BNIPDaCHM, 
compared to control cells. Finally, a higher loss of membrane integrity (i.e., 
appearance of late apoptotic cells) was observed with etoposide (10 µM), compared to 
5 µM BNIPDaCHM, after 24 hours (data not shown). 
For the quantitative detection of early apoptotic cells, PS exposure and cell 
membrane integrity/permeability was determined by Annexin V-FITC. Annexin V-
FITC specifically binds to exposed PS residues on the outer layer of the plasma 
membrane and hence stains early apoptotic cells. However, 7-AAD labels cells when 
plasma membrane integrity has been lost thus, necrotic cells. After 0.5, 4 and 6 hours, 
no significant difference in the percentage of cells labelled annexin V-FITC positive 
or 7-AAD was observed in 5 µM BNIPDaCHM-treated MDA-MB-231 cells, 
compared to control cells (Fig. 4B and 4C). However, a trend for increased annexin 
V-FITC and 7-AAD labelling in cells treated with BNIPDaCHM indicated a loss of 
plasma membrane integrity (Fig. 4C). These results correlate with the AO/EtBr 
staining observational study (Fig. 4A) but, no significant differences were observed.    
   
3.3. Cell cycle instability is associated with activation of DNA strand breakage 
 Cell cycle instability is initiated via activation of DNA damage responses 
following genotoxic stress. An alkaline Comet assay was used to detect DNA strand 
breakages in BNIPDaCHM-treated MDA-MB-231 cells. The results indicate that 
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BNIPDaCHM (0.1-10 µM after 4 and 24 hours) induced a statistically significant 
dose dependent increase in DNA strand breakage, compared to endogenous levels 
(Fig. 5A and 5B). Also, MDA-MB-231 cells were significantly more sensitive to 
BNIPDaCHM treatment than the non-tumourigenic MCF-10A cell line: (251 vs 154 
DNA strand breaks in MDA-MB-231 vs MCF-10A cells after 4 hours treatment with 
0.1 µM BNIPDaCHM and, 335 vs 181 DNA strand breaks with 5 µM BNIPDaCHM 
(P<0.01) (data shown for BNIPDaCHM concentrations used in subsequent 
experiments). An increase in double strand breaks (DSBs) was shown by significantly 
increased levels of γ-H2AX-foci, compared to the control (Fig. 5C and 5D); with the 
maximum level of γ-H2AX-foci in MDA-MB-231 cells was observed at 24 hours 
with 5 µM BNIPDaCHM (Fig. 5C and 5D). This is the first time that DNA damage 
via DSBs produced after treatment with BNIPDaCHM has been qualitatively 
identified in vitro. 
γ-H2AX-foci expression was also used to assess if the effect of BNIPDaCHM 
treatment on DNA damage was transient. MDA-MB-231 cells were washed free of 
BNIPDaCHM and allowed to recover in fresh medium for 2 hours. Results showed a 
persistence of BNIPDaCHM-induced DNA DSBs compared to the control and similar 
findings were observed when DNA repair of H2O2-induced DNA strand breakage was 
quantified after 4 and 24 hours pre-treatment with BNIPDaCHM. Cells were unable 
to effectively repair H2O2-induced DNA strand breaks; with MDA-MB-231 cell repair 
mechanisms significantly delayed (Fig. 5E and 5F). 
 Induction of DNA damage, particularly DSBs, may involve tumour protein 
p53, which can induce cell cycle instability via transcriptional targets, such as, 
p21Waf/Cip1. Gene expression analysis, via RT-PCR, of MDA-MB-231 cells treated 
with BNIPDaCHM for up to 4 hours revealed no alteration in p53 mRNA levels (Fig. 
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6A). However, a significant time dependent increase (25%) in p21Waf/Cip1 mRNA 
levels was observed (Fig. 6B), suggesting that BNIPDaCHM treatment modulates 
DNA damage independently from p53.  
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4. Discussion 
In this study, the mechanism of action of a novel bisnaphthalimidopropyl 
derivative, BNIPDaCHM, was investigated in one of the most commonly studied 
TNBC cell lines. MDA-MB-231 cells are a highly aggressive and invasive TNBC cell 
line which provides an ideal in vitro model to determine the potential use of 
BNIPDaCHM in the treatment of TNBC. TNBC disease models, such as, MDA-MB-
231, MDA-MB-468, HCC1806, BT-549, Cal-51 cells have recently been used to 
determine the potential anti-cancer effects of halogenated pyrrolo[3,2-d]pyrimidines 
[29], 6,7-bis(hydroymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles [30] or celastrol [31], 
poly(ADP-ribose) polymerase inhibitors [32], and also, propolis and its derivative 
caffeic acid phenethyl ester [33], to name a few. 
This present study delineates the underlying mechanisms utilised by 
BNIPDaCHM. A significant decrease in cell viability in a concentration (≥ 5 µM) and 
time (≥ 24 hours) dependent manner were observed. The mechanism of growth 
inhibition observed after treatment with BNIPDaCHM involved significant DNA 
strand breaks; identified for the first time to be DSBs observed by the increased 
expression of γ-H2AX-foci: a specific and sensitive surrogate marker for DNA DSBs 
[34]. Moreover, treatment with non-genotoxic concentrations of BNIPDaCHM 
induced a significant decrease in the repair of DNA strand breaks induced by H2O2. 
Also, an increase in the sub-G1 cell population (i.e., DNA fragmentation) 
corroborated the visual changes to cell morphology and plasma membrane 
integrity/permeability observed with BNIPDaCHM which indicated cell death.. Thus, 
interestingly, BNIPDaCHM’s time-dependent influence on DNA repair capacity has 
identified a novel mechanism of action for bisnaphthalimide derivatives in a TNBC 
cell line. Also, BNIPDaCHM treatment resulted in p53-independent expression of 
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p21Waf1/Cip1 suggesting that the requirement of p53 activation was not essential for 
BNIPDaCHM cytotoxicity: significant treatment effects were observed in a cell line 
with mutant p53. This study has shown the specific mechanism of action utilised by a 
bisnaphthalimidopropyl derivative in MDA-MB-231 cells and, has therefore 
identified a potentially novel anti-cancer agent. 
Induction of cell cycle instability occurs in response to various stresses, 
including DNA damage. It is well known that cells have an inherent ability to 
effectively remove and repair DNA damage but, if repair mechanisms in the cell are 
faulty or the cell is overwhelmed by damage, chances are that the cells will be unable 
to repair and the damaged cell will be removed by apoptosis. DNA DSB damage 
directly induced by BNIPDaCHM is the key component in the toxicity of 
BNIPDaCHM in MDA-MB-231 cells. This mechanism is also consistent with other 
novel naphthalimide [35] and bisnaphthalimide derivatives [16, 24].  
Finally, previous research has focused on the vital role of p53 in the 
mechanism of novel naphthalimide derivatives in p53 wild-type cancer cells [36, 37]; 
however, to the author’s best knowledge, no research is available to reveal the 
mechanism(s) of the anti-cancer effect of bisnaphthalimide derivatives, particularly in 
mutant p53 cancer cells. Common in tumours is the generation of non-functional 
phenotypes which occur by mutations in p53 [38] and, although the frequency of 
mutations is lower in breast tumours than in other tumour types, mutant status can be 
positively associated with disease aggressiveness and overall tumour cell survival [39, 
40]. It is therefore important that anti-cancer drugs are developed that can specifically 
target cells independent of their p53 status. This effect was observed for 
BNIPDaCHM in MDA-MB-231 breast cancer cells, which have a mutant, non-
functional form of p53; with significant cytotoxicity and cell death. It has also been 
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shown that, in response to DNA damage, MDA-MB-231 cells undergo increased p53-
independent expression of p21Waf1/Cip1 and altered DNA repair capacity. The elevation 
of p21Waf1/Cip1 expression through p53-independent pathways is not a new concept as 
it has been described in various cell types [41, 42]. However, this proposed 
mechanism of action is novel for a bisnaphthalimide derivative and thus, offers a 
significant therapeutic option for tumours with mutant p53, which is the direct cause 
of resistance to chemotherapy. 
In conclusion, BNIPDaCHM treatment in MDA-MB-231 cells induced a 
significant induction of DNA DSBs and inhibition of DNA repair at non-genotoxic 
concentrations via p53-independent expression of p21Waf1/Cip1 leading to cell death and 
the latter may be a consequence of a novel interaction between BNIPDaCHM and 
MDA-MB-231 cells. Further studies are warranted to provide a comprehensive 
assessment into the mechanism(s) of action of BNIPDaCHM and, the future design 
and development of bisnaphthalimide-based therapeutics, in different TNBC cell 
lines, to challenge the current treatment options available to breast cancers that are 
resistant to conventional chemotherapy.   
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Figure Legends 
 
 
Fig. 1. Structure of bisnaphthalimidopropyl diaminocyclohexylmethane 
(BNIPDaCHM). 
 
Fig. 2. BNIPDaCHM reduced MDA-MB-231 cell viability. Dose-response curves. 
Cytotoxicity was determined by MTT assay. Results were obtained after treating 
MDA-MB-231 cells with different concentrations (0-40 µM) of BNIPDaCHM over 
72 hours. Data are mean±SEM of 3 independent experiments (n=3). *P<0.05, 
**P<0.01 vs. DMSO-treated cells.  
 
Fig. 3. BNIPDaCHM induced cell cycle instability. (A) Histograms of cell cycle 
distribution of MDA-MB-231 cells treated with BNIPDaCHM (5 µM) or etoposide 
(10 µM), with DMSO (0.025% v/v) as the solvent control, after 24 hours. Line 
markers (left to right) indicate the approximate cell cycle phases: sub-G1, G1, S and 
G2/M. Histograms are representative of 4 independent experiments (n=4). (B) 
Quantification of cell cycle profiles determined by flow cytometry via PI staining 
after 24 hours treatment with BNIPDaCHM (5 µM) or etoposide (10 µM), with 
DMSO (0.025% v/v) as the solvent control. 10,000 single events were recorded and 
the percentage of the cell population in sub-G1, G1, S and G2/M were calculated from 
histograms of linear FL-2 plots in the gated region. Data are presented as mean±SEM 
of 4 independent experiments, conducted in duplicate (n=4). *P<0.05, **P<0.01, 
***P<0.001 vs. DMSO-treated cells.  
 
Fig. 4. BNIPDaCHM induced changes in plasma membrane integrity (A) Changes in 
cell morphology determined by AO/EtBr staining after 0.5, 6 and 24 hours treatment 
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with BNIPDaCHM (5 µM). Images are representative of 3 independent experiments, 
conducted in duplicate (n=3). Arrows indicate viable cells (white arrow); early 
apoptotic cells (yellow arrow) and late apoptotic cells (red arrow). Magnification 
x200. (B) Histograms of apoptotic (1-4) and (C) necrotic (1-4) distribution of MDA-
MB-231 cells. MDA-MB-231 cells (untreated: 1) were treated for 0.5 hours with 
DMSO (0.025% v/v) (2), 5 µM BNIPDaCHM (3) and 3% (v/v) formaldehyde (4) and 
stained with annexin V-FITC/7-AAD before flow cytometric analysis. Histograms are 
representative of 3 independent experiments (n=3). (D) Quantification of 
phosphatidylserine (PS) exposure and membrane integrity determined by flow 
cytometry following annexin V-FITC staining and 7-AAD labelling after 0.5, 4 and 6 
hours treatment with BNIPDaCHM (5 µM). 10,000 single events were recorded. The 
percentage of cells labelled with annexin V but, not 7-AAD, were denoted % annexin 
positive whilst cells labelled with 7-AAD were denoted as %7-AAD positive. Data 
are mean±SEM of 3 independent experiments, conducted in duplicate (n=3).   
 
Fig. 5. (A) Representative images of BNIPDaCHM-induced DNA damage (strand 
breaks) in MDA-MB-231 cells determined by Comet assay under alkaline conditions 
after 24 hours. (B) Quantification of DNA damage (strand breaks) was obtained after 
treating MDA-MB-231 cells with BNIPDaCHM (0-10 µM) for 4 and 24 hours. 
Camptothecin (10 µM; 2 hours, at 37 °C) and H2O2 (200 µM; 5 minutes, on ice) were 
used as positive controls. Data are mean±SEM of 2 independent experiments, 
conducted with 8 replicates (n=2). *P<0.05, **P<0.01 vs. DMSO-treated cells. (C) 
Representative images of -H2AX-foci expression in MDA-MB-231 cells. MDA-MB-
231 cells were treated with BNIPDaCHM (0.1 or 5 µM) for 4 and 24 hours, at 37 °C, 
and with Camptothecin (10 µM; 2 hours at 37 °C) + 2 hr recovery before detection. 
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Staining of -H2AX-foci (Green as indicated by white arrows) and DNA (Blue) were 
detected using an γ-H2AX monoclonal antibody and DAPI, respectively. Images are 
representative of 3 independent experiments, conducted in duplicate (n=3). 
Magnification x400.(D) For quantification, γ-H2AX stained nuclei and DAPI stained 
nuclei in treated MDA-MB-231 cells were taken and analysed using QCapture Pro 
6.0. γ-H2AX stained nuclei/DAPI stained nuclei ratio was calculated and expressed as 
a percentage. Data are mean±SEM of 3 independent experiments, conducted in 
duplicate (n=3). *P<0.05, **P<0.01 vs. DMSO-treated cells. Repair of DNA strand 
breaks in MDA-MB-231 cells. Cells were pre-treated in the presence (□) or absence 
(●) of non toxic BNIPDaCHM concentrations of 0.1 µM for 4 hours (E) or 1 µM for 
24 hours (F). Cells were incubated with H2O2 (200 µM, for 5 minutes on ice) and 
allowed to repair for up to 24 hours. At intervals during the 24 incubation, DNA 
strand breaks were analysed immediately (0 hours) or, after 2, 4, 8 and 24 hours, by 
Comet assay. UT represents cells which were not incubated with H2O2. Data are 
mean±SEM of 2 independent experiments, conducted with 8 replicates (n=2).  
*P<0.05, **P<0.01, ***P<0.001 vs. absence of BNIPDaCHM at each corresponding 
time point.   
 
Fig. 6. BNIPDaCHM increased p21Waf/Cip1 gene expression. Expression levels of p53 
(A) and p21Waf/Cip1 genes (B) in BNIPDaCHM-treated MBA-MB-231 cells by RT-
PCR. MDA-MB-231 cells were treated with BNIPDaCHM (5 µM) for 1 or 4 hours. 
Total RNA was extracted and RT-PCR conducted with p53 and p21Waf/Cip1 specific 
primers and β-actin as an internal control. Data are mean±SEM of 3 independent 
experiments, conducted in duplicate (n=3). **P<0.01 vs. DMSO-treated cells. 
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Table Legends 
 
Table 1. Primers used in semi-quantitative polymerase chain reaction studies  
 
Table 2. Cytotoxicity of BNIPDaCHM in MDA-MB-231 cells  
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Fig. 1. 
 
 
 
  
31 
 
Fig. 2. 
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Fig. 3. 
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Fig. 4. 
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Fig. 5. 
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Fig. 6. 
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Table 1 
 
 
Primer Sequence Product size (bp) 
p53 F 
p53 R 
CCAGGGCAGCTACGGTTTC 
CTCCGTCATGTGCTGTGACTG 
205 
p21 Waf1/Cip1 F CCTGTCACTGTCTTGTACCCT 130 
p21 Waf1/Cip1 R GCGTTTGGAGTGGTAGAAATCT  
β-actin F CATGTACGTTGCTATCCAGGC 250 
β-actin R CTCCTTAATGTCACGCACGAT  
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Table 2 
 
 
Cell Line IC50¹ (µM) 
 4 hours 24 hours 48 hours 72 hours 
MDA-MB-231 > 40 6.8±0.1 5.2±0.6 4.6±0.9 
 
1IC50 is the concentration required to inhibit cell growth by 50% of DMSO-treated cells 
(Dance et al. 2005). Cytotoxicity was determined by MTT assay. The results were obtained 
after treating MDA-MB-231 cells with different concentrations (0.01-40 µM) of 
BNIPDaCHM for over 72 hours at 37 °C. Data are mean±SEM of 3 independent experiments 
(n=3).   
  
